Open an account

Sera Prognostics

SERA · NASDAQ

$2.03+$0.00 (+0.00%)TodayMarket closed ·
Prev close $2.03

About SERA

Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. The company is headquartered in Salt Lake City, Utah and currently employs 71 full-time employees. The company went IPO on 2021-07-15. The company has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.

Employees
71
Headquarters
Salt Lake City, Utah
Listed
Jul 15, 2021
Sector
Health Care
Industry
Biotechnology
Website
sera.com

SERA key statistics

Market cap
80.08M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
9.90K
Volume
31.25K
Open price
$2.04
High today
$2.06
Low today
$2.03
52 Week high
$3.95
52 Week low
$1.56

Sera Prognostics (SERA) at a glance

Sera Prognostics (SERA) last traded at $2.03, with a market cap of 80.08M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.03 and $2.06. The current price is 0.2% above the day's low and 1.5% below its high.

Volume so far is 31.25K shares, above the average of 9.90K shares a day.

Over the past year Sera Prognostics has ranged from $1.56 to $3.95, and now sits 20% of the way up that range.

Sera Prognostics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.18 per share against an estimate of -$0.1581.

The average analyst price target is $5.61, 176.4% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $5.61
Low
$5.05
Now
$2.03
High
$6.30

SERA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 21.0% on average.

  1. Q3 FY24: reported -$0.24 per share against an estimate of -$0.2244
  2. Q4 FY24: reported -$0.25 per share against an estimate of -$0.2448
  3. Q1 FY25: reported -$0.20 per share against an estimate of -$0.2346
  4. Q2 FY25: reported -$0.16 per share against an estimate of -$0.2295
  5. Q3 FY25: reported -$0.16 per share against an estimate of -$0.204
  6. Q4 FY25: reported -$0.16 per share against an estimate of -$0.1938
  7. Q1 FY26: reported -$0.17 per share against an estimate of -$0.17
  8. Q2 FY26: reported -$0.18 per share against an estimate of -$0.1581

SERA news

  • Press releasePRNewswire

    1 in 10 U.S. Babies Are Born Too Early. A Leading OB-GYN Says Most Mothers Can Learn Their Risk by Week 21, and Do Something About It.

  • Press releasePRNewswire

    SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER

  • Press releasePRNewswire

    SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

  • Press releasePRNewswire

    SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026

  • Press releasePRNewswire

    PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE

  • Press releasePRNewswire

    SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS

  • Press releasePRNewswire

    SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTH

  • Press releasePRNewswire

    SERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY

Similar companies

Companies in the same industry as Sera Prognostics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.